Abstract

Elasmogen’s world-leading proprietary product class, soloMERs™, are fully humanized, clinical candidate, single chain, protein domains. They are small (9% of the size of an antibody), stable, and soluble and bind with high affinity and selectivity to target. soloMERs have four loops of diversity creating an unusual topology capable of binding into cryptic or hidden epitopes on the target molecule.
The company is using its expertise in early and later-stage pre-clinical development to rapidly advance a series of locally delivered protein products with an initial focus in ophthalmology and oncology. In collaboration with Amgen, Elasmogen is also developing a new class of intracellular biologics capable of bridging the drug-target gap between small molecules and large protein therapeutics.
This presentation will provide a background to Elasmogen's soloMER technology platform and product pipeline with an emphasis on the preference of these domains to bind unique epitopes.